Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 13, 2004 - Issue 4
Submit an article Journal homepage
97
Views
16
CrossRef citations to date
0
Altmetric
Review

Remyelinating and neuroprotective treatments in multiple sclerosis

Martin Stangel Department of Neurology, Medical School Hannover, Carl-Neuberg-Str. 1, 30625 Hannover, Germany. [email protected]
Pages 331-347 | Published online: 02 Mar 2005

Bibliography

  • WINGERCHUCK DM, LUCCHINETTI C, NOSEWORTHYJH: Multiple sclerosis: current pathophysiological concepts. Lab. Invest. (2001) 81:263–281.
  • COMPSTON A, COLES A: Multiple sclerosis. Lancet (2002) 359:1221–1231.
  • HEMMER B, ARCHELOS JJ, HARTUNG H-P: New concepts in the pathogenesis of multiple sclerosis. Nature Rev NeuroscL (2002) 3:291–301.
  • STEINMAN L, MARTIN R, BERNARD C, CONLON P, OKSENBERG JR: Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. Ann. Rev. NeuroscL (2002) 25:491–505.
  • •Review summarising the latest developments in MS research achieved by new technologies and its implications on the pathophysiology and therapy of MS.
  • BRADL M, HOHLFELD R: Molecular pathogenesis of neuroinflammation. NeuroL Neurosurg. Psychiatry (2003) 74:1364–1370.
  • LASSMANN H, RAINE CS, ANTEL JP,PRINEAS JW: Immunopathology of multiple sclerosis: report on an international meeting held at the Institute of Neurology of the University of Vienna. Neuroinonunol (1998) 86:213–217.
  • KORNEK B, LASSMANN H: Neuropathology of multiple sclerosis-new concepts. Brain Res. Bull. (2003) 61:321–326.
  • •Review article summarising the latest implications of neuropathological data to the pathophysiological concepts of MS.
  • GOODIN DS, FROHMAN EM, GARMANY GPJR et al: Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology (2002) 58:169–178.
  • ••Guidelines for the available treatments inMS including a thorough summary of clinical trial data.
  • KIESEIER BC, HARTUNG H-P: Currentdisease-modifying therapies in multiple sclerosis. Seinin. Neurol (2003) 23:133–146.
  • BUNGE MB, BUNGE RP, RIS H: Ultrastructural study of remyelination in an experimental lesion in the adult cat spinal cord. j Biophys. Biochem. Cytol. (1961) 10:67–94.
  • •Historically important paper showing, for the first time, spontaneous remyelination in the vertebrate CNS.
  • SMITH KJ, BLAKEMORE WF, McDONALD WI: Central remyelination restores secure conduction. Nature (1979) 280:395–396.
  • SMITH KJ, BLAKEMORE WF, McDONALD WI: The restoration of conduction by central remyelination. Brain (1981) 104:383–404.
  • MERRILL JE, SCOLDING NJ: Mechanisms of damage to oligodendrocytes and their relevance to disease. Neuropath. Appl. Neurobiol (1999) 25:435–458.
  • LUCCHINETTI C, BROCK W, PARISI J, SCHEITHAUER B, RODRIGUEZ M, LASSMANN H: A quantitative analysis of oligodendrocytes in multiple sclerosis. A study of 113 cases. Brain (1999) 122:2279–2295.
  • ••Detailed characterisation of the variousoligodendrocyte responses in MS lesions.
  • OZAWA K, SUCHANEK G, BREITSCHOPF H et al.: Patterns of oligodendroglia pathology in multiple sclerosis. Brain (1994) 117:1311–1322.
  • BROCK W, SCHMIED M, SUCHANEK G et al.: Oligodendrocytes in the early course of multiple sclerosis. Ann. Neurol (1994) 35:65–73.
  • TRAPP BD, PETERSON J, RANSOHOFF RM, RUDICK R, MORK S, BO L: Axonal transection in the lesions of multiple sclerosis. N Engl. Med. (1998) 338:278–285.
  • •Demonstration of axonal damage using modern methods. Although previously known, subsequent to this publication, the awareness of axonal injury in MS has dramatically changed.
  • LASSMANN H: Axonal injury in multiple sclerosis. I Neurol Neurosurg. Psychiatry (2003) 74:695–697.
  • KUHLMANN T, LINGFELD G, BITSCH A, SCHUCHARDT J, BROCK W: Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain (2002) 125:2202–2212.
  • MEDANA I, MARTINIC MA, WEKERLE H, NEUMANN H:
  • •• Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes. Jim. .1 Patna (2001) 159:809–815.
  • BJARTMAR C, KINKEL RP, KIDD G, RUDICK RA, TRAPP BD: Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology (2001) 57:1248–1252.
  • DE STEFANO N, MATTHEWS PM, LIQUN F et al.: Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain (1998) 121:1469–1477.
  • BJARTMAR C, KIDD G, MORK S, RUDICK R, TRAPP BD: Neurological disability correlates with spinal cord axonal loss and reduced N-acatyl aspartate in chronic multiple sclerosis patients. Ann. Neurol (2000) 48:893–901.
  • SELMAJ KW, FAROOQ M, NORTON WT, RAINE CS, BROSNAN CF: Proliferation of astrocytes in vitro in response to cytokines. A primary role for tumour necrosis factor. lonnunol (1990) 144:129–135.
  • ROSEN CL, BUNGE RP, ARD MD, WOOD PM: Type 1 astrocytes inhibit myelination by adult rat oligodendrocytes in vitro. Neurosci. (1989) 9:3371–3379.
  • RIDET JL, MALHOTRA SK, PRIVAT A, GAGE FH: Reactive astrocytes: cellular and molecular cues to biological function. Trends Neurosci. (1997) 20:570–577.
  • HORNER PJ, PALMER TD: New roles for astrocytes: the nightlife of an `astrocyte'. La vida local Trends Neurosci. (2003) 26:597–603.
  • LASSMANN H, BROCK W, LUCCHINETTI C: Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Ma Med. (2001) 7:115–121.
  • LUCCHINETTI C, BROCK W, PARISI J, SCHEITHAUER B, RODRIGUEZ M, LASSMANN H: Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol (2000) 47:707–717.
  • ••Together with [30] this article describes theheterogeneity of MS lesions and characterises the four subtypes.
  • LUCCHINETTI CF, BROCK W, RODRIGUEZ M, LASSMANN H: Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Patna (1996) 6:259–274.
  • •See [29].
  • LASSMANN H, REINDL M, RAUSCHKA H et al.: New paraclinical CSF marker for hypwda-like tissue damage in multiple sclerosis lesions. Brain (2003) 126:1347–1357.
  • ABOUL ENEIN F, RAUSCHKA H, KORNEK B et al.: Preferential loss of myelin associated glycoprotein reflects hypwda-like white matter damage in stroke and inflammatory brain diseases. Neuropathol Exp. Neurol (2003) 62:25–33.
  • PRINEAS JW, BARNARD RO, KWON EE, SHARER LR, CHO E-S: Multiple sclerosis: remyelination of nascent lesions. Ann. Neurol (1993) 33:137–151.
  • RAINE CS, WU E: Multiple sclerosis: remyelination in acute lesions. Neuropathol Exp. Neurol (1993) 52:199–204.
  • BLAKEMORE WF: Pattern of remyelination in the CNS. Nature (1974) 249:577–578.
  • BLAKEMORE WE KEIRSTEAD HS: The origin of remyelinating cells in the central nervous system.' Neurohninunol (1999) 98:69–76.
  • FRANKLIN RJM, HINKS GL: Understanding CNS remyelination: clues from developmental and regeneration biology. Neurosci. Res. (1999) 58:207–213.
  • FRANKLIN RJM: Why does remyelination fail in multiple sclerosis? Nat. Rev Neurosci. (2002) 3:705–714.
  • •Excellent review on why remyelination is impaired in MS.
  • BAUMANN N, PHAM-DINH D: Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol Rev (2001) 81:871–927.
  • ALTHAUS HH, KLOPPNER S, SCHMIDT-SCHULTZ T, SCHWARTZ P: Nerve growth factor induces proliferation and enhances fibre regeneration in oligodendrocytes isolated from adult pig brain. Neurosci. Lett. (1992) 135:219–223.
  • BANSAL R: Fibroblast growth factors and their receptors in oligodendrocyte development: implications for demyelination and remyelination. Dev. Neurosci. (2002) 24:35–46.
  • BARRES BA, RAFF MC, GAESE F, BARTKE I, DECHANT G, BARDE YA: A crucial role for neurotrophin-3 in oligodendrocyte development. Nature (1994) 367:371–375.
  • CANOLL PD, MUSACCHIO JM, HARDY R, REYNOLDS R, MARCHIONNI MA, SALZER JL: GGF/neuregulin is a neuronal signal that promotes the proliferation and survival and inhibits the differentiation of oligodendrocyte progenitors. Neuron (1996) 17:229–243.
  • FROST EE, NIELSEN JA, LE TQ, ARMSTRONG RC: PDGF and FGF2 regulate oligodendrocyte progenitor responses to demyelination. Neurobiol (2003) 54:457–472.
  • MASON JL, JONES JJ, TANIIKE M, MORELL P, SUZUKI K, MATSUSHIMA GK: Insulin-like growth factor-1 inhibits mature oligodendrocyte apoptosis during primary demyelination. NeuroscL (2000) 20:5703–5708.
  • MAYER M, BHAKOO K, NOBLE M: Ciliary neurotrophic factor and leukaemia inhibitory factor promote the generation, maturation and survival of oligodendrocytes in vitro. Development (1994) 120:143–153.
  • NOBLE M, MURRAY K, STROOBANT P, WATERFIELD MD, RIDDLE P: Platelet-derived growth factor promotes division and motility and inhibits premature differentiation of the oligodendrocyte/type-2 astrocyte progenitor cell. Nature (1988) 333:560–562.
  • RAFF M, LILLIEN LE, RICHARDSON WD, BURNE JF, NOBLE M: Platelet-derived growth factor from astrocytes drives the clock that times oligodendrocyte development in culture. Nature (1988) 333:562–565.
  • WOLSWIJK G, NOBLE M: Cooperation between PDGF and FGF converts slowly dividing 0-2A(adult) progenitor cells to rapidly dividing cells with characteristics of 0-2A(perinatal) progenitor cells. Cell Biol. (1992) 118:889–900.
  • HINKS GL, FRANKLIN RJM: Distinctive patterns of PDGF-A, FGF-2, IGF-1 and TGF-131 gene expression during remyelination of experimentally-induced spinal cord demyelination. Ma Cell. NeuroscL (1999) 14:153–168.
  • HINKS GL, FRANKLIN RJM: Delayed changes in growth factor gene expression during slow remyelination in the CNS of aged rats. Ma Cell. Neurosci. (2000) 16:542–556.
  • MESSERSMITH DJ, MURTIE JC, LE TQ, FROST EE, ARMSTRONG RC: Fibroblast growth factor 2 (FGF2) and FGF receptor expression in an experimental demyelinating disease with extensive remyelination. Neurosci. Res. (2000) 62:241–256.
  • McKINNON RD, PIRAS G, IDA JA, DUBOIS-DALQ M: A role for TGF- 13 in oligodendrocyte differentiation. J. Cell Biol. (1993) 121:1397–1407.
  • AGRESTI C, D'URSO D, LEVI G: Reversible inhibitory effects of interferon-y and tumour necrosis factor-a on oligodendroglial lineage cell proliferation and differentiation M vitro. Ear: J. Neurosci. (1996) 8:1106–1116.
  • CANNELLA B, RAINE CS: Multiple sclerosis: cytokine receptors on oligodendrocytes predict innate regulation. Ann. Neurol (2004) 55:46–57.
  • NGUYEN D, STAN GEL M: Expression of the chemokine receptors CXCR1 and CXCR2 in rat oligodendroglial cells. Dev. Brain. Res. (2001) 128:77–81.
  • TSAI H-H, FROST E, TO V et al.: The chemokine receptor CXCR2 controls positioning of oligodendrocyte precursors in developing spinal cord by arresting their migration. Cell (2002) 110:373–383.
  • KNAPP PE, MADERSPACH K, HAUSER KF: Endogenous opioid system in developing normal and Jimpy oligodendrocytes: mu and kappa opioid receptors mediate differential mitogenic and growth responses. Clio (2000) 22:189–201.
  • BARRES BA, LAZAR MA, RAFF MC: A novel role for thyroid hormone, glucucorticoids and retinoic acid in timing oligodendrocyte development. Development (1994) 120:1097–1108.
  • CHARLES P, HERNANDEZ MP, STANKOFF B et al.: Negative regulation of central nervous system myelination by polysialyated-neural cell adhesion molecule. Proc. Natl. Acad. Sci. (2000) 97:7585–7590.
  • CHARLES P, REYNOLDS R, SEILHEAN D et al.: Reexpression of PSA-NCAM by demyelinated axons: an inhibitor of remyelination in multiple sclerosis? Brain (2002) 125: 1972-1979.
  • •Description of a possible crucial role for PSA-NCAM in remyelination in MS.
  • KERSCHENSTEINER M, GALLMEIER E, BEHRENS L et al: Activated human T cells, B cells and monocytes produce brain-derived neurotrophic factor M vitro and in inflammatory brain lesions: a neuroprotective role in inflammation? J. Exp. Med. (1999) 189:865–870.
  • ••Together with [63] demonstrates theexpression of growth factors in inflammatory cells in MS lesions and thus provides evidence for a cross-talk between the immune and nervous system.
  • STADELMANN C, KERSCHENSTEINER M, MISGELD T, BROCK W, HOHLFELD R, LASSMANN H: BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain (2002) 125:75–85.
  • •See [62].
  • KOTTER MR, SETZU A, SIM FJ, VAN ROOIJEN N, FRANKLIN RJM: Macrophage depletion impairs oligodendrocyte remyelination following lysolecithin-induced demyelination. Clio (2001) 35:204–212.
  • BIEBER AJ, KERR S, RODRIGUEZ M: Efficient central nervous system remyelination requires T cells. Ann. Nemo]. (2003) 53:680–684.
  • TOURBAH A, LINNINGTON C, BACHELIN C, AVELLANA-ADALID V, WEKERLE H, BARON-VAN EVERCOOREN A: Inflammation promotes survival and migration of the CG4 oligodendrocyte progenitors transplanted in the spinal cord of both inflammatory and demyelinated EAE rats. Neurosci. Res. (1997) 50:853–861.
  • KEIRSTEAD HS, LEVINE JM, BLAKEMORE WF: Response of the oligodendrocyte progenitor cell population (defined by NG2 labelling) to demyelination of the adult spinal cord. Clio (1998) 22:161–170.
  • BLAKEMORE WF, GILSON JM, CRANG AJ: Transplanted glial cells migrate over a greater distance and remyelinate demyelinated lesions more rapidly than endogenous remyelinating cells. J. Neurosci. Res. (2000) 61:288–294.
  • SCOLDING N, FRANKLIN R, STEVENS S, HELDIN C-H, COMPSTON A, NEWCOMBE J: Oligodendrocyte progenitors are present in the normal adult human CNS and in lesions of multiple sclerosis. Brad) (1998) 121:2221–2228.
  • CHANG A, NISHIYAMA A, PETERSON J, PRINEAS J, TRAPP BD: NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. I Neurosci. (2000) 20:6404–6412.
  • WOLSWIJK G: Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. J. Neurosci. (1998) 18:601–609.
  • MAEDA Y, SOLANKY M, MENONNA J,CHAPIN J, LI W, DOWLING P: Platelet-derived growth factor-a receptor-positive oligodendroglia are frequent in multiple sclerosis lesions. Ann. Neurol (2001) 49:776–785.
  • CHANG A, TOURTELLOTTE WW, RUDICK R, TRAPP BD: Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl. J. Med. (2002) 346:165–173.
  • •Demonstration of OPC in MS lesions that are not able to remyelinate and thus implying that the failure for remyelination is not due to lacking OPC.
  • PENDERIS J, SHIELDS SA, FRANKLIN RJM: Impaired remyelination and depletion of oligodendrocyte progenitors does not occur following repeated episodes of focal demyelination in the rat central nervous system. Brad) (2003) 126:1382–1391.
  • WANG S, SDRULLA AD, DISIBIO G et al.: Notch receptor activation inhibits oligodendrocyte differentiation. Neuron (1998) 21:63–75.
  • JOHN GR, SHANKAR SL, SHAFIT-ZAGARDO B et al.: Multiple sclerosis: reexpression of a developmental pathway that restricts oligodedrocyte maturation. Nat. Med. (2002) 8:1115–1121.
  • VIEHOVER A, MILLER RH, PARK S-K, FISCHBACH G, VARTANIAN T: Neuregulin: An oligodendrocyte growth factor absent in active multiple sclerosis lesions. Dev. Neurosci. (2001) 23:377–386.
  • SIM FJ, ZHAO C, PENDERIS J, FRANKLIN RJM: The age-related decrease in CNS remyelination efficiency is attributable to an impairment of both oligodendrocyte progenitor recruitment and differentiation. Neurosci. (2002) 22:2451–2459.
  • MOALEM G, LEIBOWITZ-AMIT R, YOLES E, MOR F, COHEN IR, SCHWARTZ M: Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat. Med. (1999) 5:49–55.
  • •Important paper demonstrating the concept of protective autoimmunity.
  • RAPALINO 0, LAZAROV-SPIEGLER 0, AGRANOV E et al.: Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nat. Med. (1998) 4:814–821.
  • SCHWARTZ M, MOALEM G, LEIBOWITZ-AMIT R, COHEN IR: Innate and adaptive immune responses can be beneficial for CNS repair. Trends Neurosci. (1999) 22:295–299.
  • SCHWARTZ M, SHAKED I, FISHER J,MIZRAHI T, SCHORI H: Protective autoimmunity against the enemy within: fighting glutamate toxicity. Trends Neurosci. (2003) 26:297–302.
  • MOALEM G, GDALYAHU A, SHANI Y et al.: Production of neurotrophins by activated T cells: implications for neuroprotective autoimmunity. Autoimmun. (2000) 15:331–345.
  • KERSCHENSTEINER M, STADELMANN C, DECHANT G, WEKERLE H, HOHLFELD R: Neurotrophic cross-talk between the nervous and immune systems: Implications for neurological diseases. Ann. Neurol (2003) 53:292–304.
  • KAPLAN MR, MEYER-FRANKE A, LAMBERT S et al.: Induction of sodium channel clustering by oligodendrocytes. Nature (1997) 386:724–728.
  • MATHIS C, DENISENKO-NEHRBASS N, GIRAULT J-A, BORRELLI E: Essential role of oligodendrocytes in the formation and maintenance of central nervous system nodal regions. Development (2001) 128:4881–4890.
  • MARCUS J, DUPREE JL, POPKO B: Myelin-associated glycoprotein and myelin galactolipids stabilize developing axo-glial interactions. J. Cell Biol. (2002) 156:567–577.
  • WILKINS A, CHANDRAN S, COMPSTON A: A role for oligodendrocyte-derived IGF-1 in tropic support of cortical neurons. Glia (2001) 36:48–57.
  • TANIIKE M, MOHRI I, EGUCHI N, BEUCKMANN CT, SUZUKI K, URADE Y: Perineuronal oligodendrocytes protect against neuronal apoptosis through the production of lipocalin-type prostaglandin D synthase in a genetic demyelinating model. J. Neurosci. (2002) 22:4885–4896.
  • WILKINS A, MAJED H, LAYFIELD R, COMPSTON A, CHANDRAN S: Oligodendrocytes promote neuronal survival and axonal length by distinct intracellular mechanisms: A novel role for oligodendrocyte-derived glial cell line-derived neurotrophic factor. J. Neurosci. (2003) 23:4967–4974.
  • JEAN I, ALLAMARGOT C, BARTHELAIX-POUPLARD A, FRESSINAUD C: Axonal lesions and PDGF-enhanced remyelination in the rat corpus callosum after lysolecithin demyelination. Neuroreport (2002) 13:627–631.
  • RODRIGUEZ M: A function of myelin is to protect axons from subsequent injury: implications for deficits in multiple sclerosis. Brain (2003) 126:751–752.
  • BARKHOF F: Imaging of remyelination. Molt. Scler. (1997) 3:129–132.
  • BROCK W, KUHLMANN T, STADELMANN C: Remyelination in multiple sclerosis. J. Neurol Sci. (2003) 206:181–185.
  • DELOIRE-GRASSIN MSA, BROCHET B, QUESSON B et al.: ha vivo evaluation of remyelination in rat brain by magnetization transfer imaging. J. Neurol Sci. (2000) 178:10–16.
  • BARKHOF F, BROCK W, DE GROOT CJ et al.: Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch. Nemo]. (2003) 60:1073–1081.
  • BARKHOF F, VAN WAESBERGHE JH, FILIPPI M et al.: Ti hypointense lesions in secondary progressive multiple sclerosis: effect of interferon I3-lb treatment. Brain (2001) 124:1396–1402.
  • NARAYANAN S, DE STEFANO N, FRANCIS GS et al: Axonal metabolic recovery in multiple sclerosis patients treated with interferon 13-lb. J. Neural. (2001) 248:979–986.
  • STANGEL M, BOEGNER F, KLATT CH, HOFMEISTER C, SEYFERT S: A placebo-controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis. NeuroL Neurosurg. Psychiatry (2000) 68:89-92. loo. ALLAMARGOT C, POUPLARD-BARTHELAIX A, FRESSINAUD C: A single intracerebral microinjection of platelet-derived growth factor (PDGF) accelerates the rate of remyelination in vivo. Brain Res. (2001) 918:28–39.
  • McKAY JS, BLAKEMORE WF, FRANKLIN RJ: The effects of the growth factor-antagonist, trapidil, on remyelination in the CNS. Neuropath. Appl. Neurobiol (1997) 23:50–58.
  • MUIR DA, COMPSTON DAS: Growth factor stimulation triggers apoptotic cell death in mature oligodendrocytes. Neurosci. Res. (1996) 44:1–11.
  • RUFFINI F, FURLAN R, POLIANI PL et al.: Fibroblast growth factor-II gene therapy reverts the clinical course and the pathological signs of chronic experimental autoimmune encephalomyelitis in C57BL/6 mice. Gene Therapy (2001) 8:1207–1213.
  • GODDARD DR, BERRY M, KIRVELL SL, BUTT AM: Fibroblast growth factor-2 inhibits myelin production by oligodendrocytes in vivo. MM. Cell. Neurosci. (2001) 18:557–569.
  • ARMSTRONG RC, LE TQ, FROST EE, BORKE RC, VANA AC: Absence of fibroblast growth factor 2 promotes oligodendroglial repopulation of demyelinated white matter. J. Neurosci. (2002) 22:8574–8585.
  • CARSON MJ, BEHRINGER RR, BRINSTER RL, McMORRIS FA: Insulin-like growth factor I increases brain growth and central nervous system myelination in transgenic mice. Neuron (1993) 10:729–740.
  • BECK KD, POWELL-BRAXTON L, WIDMER HR, VALVERDE J, HEFTI F: IGF1 gene disruption results in reduced brain size, CNS hypomyelination and loss of hippocampal granule and stiatal parvalbumin-containing neurons. Neuron (1995) 14:717–730.
  • MASON J, XUAN S, DRAGATSIS I, EFSTRATIADIS A, GOLDMAN JE: Insulin-like growth factor (IGF) signalling through Type 1 IGF receptor plays an important role in remyelination. Neurosci. (2003) 23:7710–7718.
  • NESS JK, WOOD TL: Insulin-like growth Factor I but not neurotrophin-3, sustains Akt activation and provides long-term protection of immature oligodendrocytes from glutamate-mediated apoptosis. Neurosci. (2002) 20:476–488.
  • YAO D-L, LIU X, HUDSON LD, WEBSTER HD: Insulin-like growth factor I treatment reduces demyelination and upregulates gene expresion of myelin-related proteins in experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA (1995) 92:6190–6194.
  • LOVETT-RACKE AE, BITTNER P, CROSS AH, CARLINO JA, RACKE MK: Regulation of experimental autoimmune encephalomyelitis with insulin-like growth factor (IGF-1) and IGF-1/IGF-binding protein-3 complex (IGF-1/IGFBP3). Clin. Invest. (1998) 101:1797–1804.
  • CANNELLA B, PITT D, CAPELLO E, RAINE CS: Insulin-like growth factor-1 fails to enhance central nervous system myelin repair during autoimmune demyelination. Am. .1. PathoL (2000) 157:933–943.
  • O'LEARY MT, HINKS GL, CHARLTON HM, FRANKLIN RJM: Increasing local levels of IGF-1 mRNA expression using adenoviral vectors does not alter oligodendrocyte remyelination in the CNS of aged rats. MoL Cell. Neurosci. (2002) 19:32–42.
  • CANNELLA B, HOBAN CJ, GAO Y-L et al.: The neuregulin, glial growth factor 2, diminishes autoimmune demyelination and enhances remyelination in a chronic relapsing model for multiple sclerosis. Proc. Natl. Acad. Sci. USA (1998) 95:10100–10105.
  • PENDERIS J, WOODRUFF RH, LAKATOS A et al.: Increasing local levels of neuregulin (glial growth factor-2) by direct infusion into areas of demyelination does not alter remyelination in the rat CNS. Ear. Neurosci. (2003) 18:2253–2264.
  • VILLOSLADA P, HAUSER SL, BARTKE I et al.: Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell Type 1 and 2 cytokines within the central nervous system. J. Exp. Med. (2000) 191:1799–1806.
  • ARREDONDO LR, DENG C, RATTS RB, LOVETT-RACKE AE, HOLTZMAN DM, RACKE MK: Role of nerve growth factor in experimental autoimmune encephalomyelitis. Ear. J. bronunol (2001) 31:625–633.
  • MICERA A, PROPERZIF, TRIACAV, ALOE L: Nerve growth factor antibody exacerbates neuropathological signs of experimental allergic encephalomyelitis in adult Lewis rats. J. Neuroimmunol (2000) 104:116–123.
  • McTIGUE DM, HORNER PJ, STOKES BT, GAGE FH: Neurotrophin-3 and brain-derived neurotrophic factor induce oligodendrocyte proliferation and myelination of regenerating axons in the contused adult rat spinal cord. Neurosci. (1998) 18:5354–5365.
  • IKEDA 0, MURAKAMI M, INO H et al: Effects of brain-derived neurotrophic factor (BDNF) on compression-induced spinal cord injury: BDNF attenuates downregulation of superoxide dismutase expression and promotes upregulation of myelin basic protein expression. Neuropathol Esp. Neurol (2002) 61:142–153.
  • JEAN I, LAVIALLE C, BARTHELAIX-POUPLARD A, FRESSINAUD C: Neurotrophin-3 specifically increases mature oligodendrocyte population and enhances remyelination after chemical demyelination of adult rat CNS. Brain Res. (2003) 972:110–118.
  • LINKER RA, MAURER M, GAUPP S et al.: CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat. Med. (2002) 8:620–624.
  • ALBRECHT PJ, MURTIE JC, NESS JK et al.: Astrocytes produce CNTF during the remyelination phase of viral-induced spinal cord demyelination to stimulate FGF-2 production. Neurobiol Dis. (2003) 13:89–101.
  • STANKOFF B, AIGROT M-S, NOEL F, WATILLIAUX A, ZALC B, LUBETZKI C: Ciliary neurotrophic factor (CNTF) enhances myelin formation: a novel role for CNTF and CNTF-related molecules. Neurosci. (2002) 22:9221–9227.
  • BUTZKUEVEN H, ZHANG SOILU-HANNINEN M et al: LIF receptor signalling limits immune-mediated demyelination by enhancing oligodendrocyte survival. Nat. Med. (2002) 8:613–619.
  • BUGGA L, GADIENT RA, KWAN K, STEWART CL, PATTERSON PH: Analysis of neuronal and glial phenotypes in brains of mice deficient in leukaemia inhibitory factor. J. Neurobiol (1998) 36:509–524.
  • SHIMOJO M, NAKAJIMA K, TAKEI N, HAMANOUE M, KOHSAKA S: Production of basic fibroblast growth factor in cultured rat brain microglia. Neurosci. Lett. (1991) 123:229–231.
  • ARAUJO DM, COTMAN CW: Basic FGF in astroglial, microglial and neuronal cultures: characterization of binding sites and modulation by lymphokines and tropic factors. J. Neurosci. (1992) 12:1668–1678.
  • PRESTA M, URBINATI C, DELL'ERA P et al.: Expression of basic fibroblast growth factor and its receptors in human fetal microglia cells. hat. Dev. Neurosci. (1995) 13:29–39.
  • BATCHELOR PE, LIBERATORE GT, WONG JYF et al.: Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. Neurosci. (1999) 19:1708–1716.
  • ARKINS S, REBEIZ N, BIRAGYN A, REESE DL, KELLEY KW: Murine macrophages express abundant insulin-like growth factor-I class I Ea and Eb transcripts. Endocrinology (1993) 133:2334–2343.
  • BAROUCH R, APPEL E, KAZIMIRSKY G, BRODIE C: Macrophages express neurotrophins and neurotrophic receptors. Regulation of nitric oxide production by NT-3. Neuronannunol (2001) 72–77.
  • NEUHAUS 0, FARINA C, YASSOURIDIS A et al: Multiple sclerosis: comparison of copolymer-l-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc. Natl. Acad. Sci. USA (2000) 97:7452–7457.
  • ZIEMSSEN T, KOMPFEL T, KLINKERT WEE NEUHAUS 0, HOHLFELD R: Glatiramer acetate-specific T helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain (2002) 125:2381–2391.
  • CHEN M, VALENZUELA PM, DHIB-JALBUT S: Galtiramer acetate-reactive T cells produce brain-derived neurotrophic factor. J. Neurol Sci. (2003) 215:37–44.
  • FRANK JA, RICHERT N, LEWIS B et al: A pilot study of recombinant insulin-like growth factor-1 in seven multiple sclerosis patients. Mult. Sclec (2002) 8:24–29.
  • LIU J, MARINO MW, WONG G et al.: TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat. Med. (1998) 4:78–83.
  • BACHMANN R, EUGSTER H-P, FRET K, FONTANA A, LASSMANN H: Impairment of TNF-receptor-1 signalling but not Fas signalling diminishes T cell apoptosis in myelin oligodendrocyte glycoprotein peptide-induced chronic demyelinating autoimmune encephalomyelitis in mice. Am. J. Athol (1999) 154:1417–1422.
  • PROBERT L, EUGSTER H-P, AKASSOGLOU K, BAUER J, LASSMANN H, FONTANA A: TNE-R1 signalling is critical for the development of demyelination and the limitation of T cell responses during immune-mediated CNS disease. Brain (2000) 123: 2005-2019.
  • LENERCEPT MULTIPLE SCLEROSIS STUDY GROUP, UNIVERSITY OF BRITISH COLUMBIA MS/MRI ANALYSIS GROUP: TNF neutralization in MS. Results of a randomized, placebo-controlled multicenter study. Neurology (1999) 53:457–465.
  • JUREWICZ A, MATYSIAK M, TYBOR K, SELMAJ K: TNF-induced death of adult human oligodendrocytes is mediated by c-jun NH2-terminal kinase-3. Brain (2003) 126:1358–1370.
  • ARNETT HA, MASON J, MARINO M, SUZUKI K, MATSUSHIMA GK, TING JPY: TNF-a promotes proliferation of oligodendrocyte progenitors and remyelination. Nat. Neurosci. (2001) 4:1116–1122.
  • ••An excellent article showing a new role forTNF-a in the promotion of remyelination.
  • GAO X, GILLIG TA, YE P, D'ERCOLE AJ, MATSUSHIMA GK, POPKO B: Interferon-7 protects against cuprizone-induced demyelination. Neurosci. (2000) 16:338–349.
  • MASON JL, SUZUKI K, CHAPLIN DD, MATSUSHIMA GK: Interleuldn- 1(3 promotes repair of the CNS. Neurosci. (2001) 21:7046–7052.
  • NJENGA MK, COENEN MJ, DECUIR N, YEH HY, RODRIGUEZ M: Short-term treatment with interferon-a/3 promotes remyelination, whereas long-term treatment aggravates demyelination in a murine model of multiple sclerosis. Neurosci. Res. (2000) 59:661–670.
  • CALABRESI PA, FIELDS NS, MALONI HW et al: Phase I trial of transforming growth factor-I3 2 in chronic progressive MS. Neurology (1998) 51:289–292.
  • TREBST C, SORENSEN TL, KIVISAKK P et al.: CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. Am. J. Athol (2001) 159:1701–1710.
  • McMANUS C, BERMAN JW, BRETT FM, STAUNTON H, FARRELL M, BROSNAN CF: MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study. Neurohninunol (1998) 86:20–29.
  • SIMPSON JE, NEWCOMBE J, CUZNER ML, WOODROOFE MN: Expression of monocyte chemoattractant protein-1 and other I3-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J. Neuroiminunol (1998) 84:238–249.
  • SORENSEN TL, TANI M, JENSEN J et al.: Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. Am. J. Patna (1999) 103:807–815.
  • ROBINSON S, TANI M, STRIETER RM, RANSOHOFF RIVI, MILLER RH: The chemokine growth-regulated oncogene-a promotes spinal cord oligodendrocyte precursor proliferation. J. Neurosci. (1998) 15:10457–10463.
  • FILIPOVIC R, JAKOVCEVSKI I, ZECEVIC N: GROa and CXCR2 in the human fetal brain and multiple sclerosis lesions. Dev. Neurosci. (2003) 25:279–290.
  • PROUDFOOT AEI: Chemokine receptors: multifaceted therapeutic targets. Nat. Rev Immunol (2002) 2:106–115.
  • CONFAVREUX C, HUTCHINSON M, HOURS MM, CORTINOVIS-TOURNIAIRE P, MOREAU T, THE PREGNANCY IN MULTIPLE SCLEROSIS GROUP: Rate of pregnancy-related relapse in multiple sclerosis. N Engl. J. Med. (1998) 339:285–291.
  • BEBO BF Jr, FYFE-JOHNSON A, ADLARD K, BEAM AG, VANDENBARK AA, OFFNER H: Low-dose oestrogen therapy ameliorates the experimental autoimmune encephalomyelitis in two different inbred mouse strains. J. Immunol (2001) 166:2080–2089.
  • KIM S, LIVA SM, DALAL MA, VERITY MA, VOSKUHL RR: Estriol ameliorates autoimmune demyelinating disease. Implications for multiple sclerosis. Neurology (1999) 52:1230–1238.
  • SICOTTE NL, LIVA SM, KLUTCH R et al.: Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann. Nemo]. (2002) 52:421–428.
  • GHOUMARI AM, IBANEZ C, EL-ETR M et al.: Progesterone and its metabolites increase myelin basic protein expression in organotypic slice cultures of rat cerebellum. J. Neurochem. (2003) 86:848–859.
  • IBANEZ C, SHIELDS SA, EL-ETR M et al.: Steroids and the reversal of age-associated changes in myelination and remyelination. Frog. Neuronic] (2003) 71:49–56.
  • RODRIGUEZ-PENA A: Oligodendrocyte development and thyroid hormone. J. Neuronic] (1999) 40:497–512.
  • JONES SA, JOLSON DM, CUTA KK, MARIASH CN, ANDERSON GW: Triiodothyronine is a survival factor fro developing oligodendrocytes. MM. Cell. Endocrinol (2003) 199:49–60.
  • CALZA L, FERNANDEZ M, GIULIANI A, ALOE L, GIARDINO L: Throid hormone activates oligodendrocyte precursors and increases a myelin-forming protein and NGF content in the spinal cord during experimental allergic encephalomyelitis. Proc. Natl. Acad. Sci. USA (2002) 99:3258–3263.
  • BAAS D, LEGRAND C, SAMARUT J, FLAMANT F: Persistence of oligodendrocyte precursor cells and altered myelination in optic nerve associated to retina degeneration in mice devoid of all thyroid hormone receptors. Proc. Natl. Acad. Sci.USA (2002) 99:2907–2911.
  • FRANKLIN RJM, GILSON JM: Remyelination in the CNS of the hypothyroid rat. Neuroreport (1996) 7:1526–1530.
  • RODRIGUEZ M, LENNON VA: Immunoglobulins promote remyelination in the central nervous system. Ann. Nemo]. (1990) 27:12–17.
  • ASAKURA K, POGULIS RJ, PEASE LR, RODRIGUEZ M: A monoclonal autoantibody which promotes central nervous system remyelination is highly polyreactive to multiple known and novel antigens..! Neuroimmunol (1996) 65:11–19.
  • ASAKURA K, MILLER DJ, MURRAY K, BANSAL R, PFEIFFER SE, RODRIGUEZ M: Monoclonal autoantibody 5CH94.03, which promotes CNS remyelination, recognizes an antigen on the surface of oligodendrocytes. .1 Neurosci. Res. (1996) 43:273–281.
  • ASAKURA K, MILLER DJ, PEASE LR, RODRIGUEZ M: Targeting of IgMk antibodies to oligodendrocytes promotes CNS remyelination. Neurosci. (1998) 18:7700–7708.
  • MILLER DJ, BRIGHT JJ, SRIRAM S, RODRIGUEZ M: Successful treatment of established relapsing experimental autoimmune encephalomyelitis in mice with a monoclonal natural autoantibody. .1 Neuroinanunol (1997) 75:204–209.
  • PAVELKO KD, VAN ENGELEN BGM, RODRIGUEZ M: Acceleration in the rate of CNS remyelination in lysolecithin-induced demyelination. Neurosci. (1998) 18:2498–2505.
  • WARRINGTON AE, ASAKURA K, BIEBER AJ et al: Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proc. Natl. Acad. Sci. USA (2000) 97:6820–6825.
  • ••This paper provides evidence that certainhuman antibodies are capable of enhancing remyelination in the CNS.
  • BIEBER AJ, WARRINGTON A, ASAKURA K et al.: Human antibodies accelerate the rate of remyelination following lysolecithin-induced demyelination in mice. Clio (2002) 37:241–249.
  • MITSUNAGA Y, CIRIC B, VAN KEULEN V et al.: Direct evidence that a human antibody derived from patient serum can promote myelin repair in a mouse model of chronic-progressive demyelinating disease. FASEB J. (2002) 16:1325–1327.
  • CIRIC B, VAN KEULEN V, PAZ SOLDAN M, RODRIGUEZ M, PEASE LR: Antibody-mediated remyelination operates through mechanism independent of immunomodulation. .1 Neuroinanunol (2004) 146:153–161.
  • PAZ SOLDAN MM, WARRINGTON AE, BIEBER AJ et al: Remyelination-promoting antibodies activate distinct Ca2+ influx pathways in astrocytes and oligodendrocytes: relationship to the mechanism of myelin repair. Ma Cell. Neurosci. (2003) 22:14–24.
  • KAZATCHKINE MD, KAVERI SV: Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl. J. Med. (2001) 345:747–755.
  • STANGEL M, HARTUNG H-P, MARX P, GOLD R: Intravenous immunoglobulin treatment of neurological autoimmune diseases. / Neurol Sci. (1998) 153:203–214.
  • SORENSEN PS, FAZEKAS F, LEE M: Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eur: .1 Neurol (2002) 9:557–563.
  • PUL R, NGUYEN D, SCHMITZ U, MARX P, STANGEL M: Comparison of intravenous immunoglobulin preparations on microglial function in vitro: more potent immunomodulatory capacity of an IgM/ IgA-enriched preparation. Clin. Neuropliannacol (2002) 25:254–259.
  • STANGEL M, BERNARD D: Polyclonal IgM influence oligodendrocyte precursor cells in mixed glial cell cultures: implications for remyelination. J. Neuroinanunol (2003) 138:25–30.
  • STANGEL M, COMPSTON A, SCOLDING NJ: Polyclonal immunoglobulins for intravenous use do not influence the behaviour of cultured oligodendrocytes. Neuroinanunol (1999) 96:228–233.
  • STANGEL M, COMPSTON A, SCOLDING NJ: Oligodendroglia are protected from antibody mediated complement injury by normal immunoglobulins J. Neuroinanunol (2000) 103:195–201.
  • STANGEL M, COMPSTON A: Polyclonal immunoglobulins (IVIg) modulate nitric oxide production and microglial functions in vitro via Fc receptors. J. Neuroimmuna (2001) 112:63–71.
  • NOSEWORTHY JH, O'BRIEN PC, WEINSHENKER BG et al.: IV immunoglobulin does not reverse established weakness in MS. A double-blind, placebo-controlled trial. Neurology (2000) 55:1135–1143.
  • NOSEWORTHY JH, O'BRIEN PC, PETTERSON TM et al.: A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology (2001) 56:1514–1522.
  • GRUNDY RI: The therapeutic potential of the cannabinoids in neuroprotection. Expert Opin. Investig. Drugs (2002) 11:1365–1374.
  • MOLINA-HOLGADO E, VELA JM, AREVALO-MARTIN A et al: Expression of cannabinoid CB1 receptors in oligodendroglial cells: activation of PI-3K/ Akt signalling pathway promotes cell survival. J. Neurosci. (2002) 22:9742–9753.
  • AREVALO-MARTIN A, VELA JM, MOLINA-HOLGADO E, BORRELL J, GUAZA C: Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J. Neurosci. (2003) 23:2511–2516.
  • •Together with [189] these articles show the neuroprotective action of cannabinoids in inflammatory animal models.
  • PRYCE G, AHMED Z, HANKEY DJR et al.: Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain (2003) 126:2191–2202.
  • •See [188].
  • ZAJICEK J, FOX P, SANDERS H et al.: Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multi-centre randomised placebo-controlled trial. Lancet (2003) 362:1517–1526.
  • DUNCAN ID, GREVER WE, ZHANG S-C: Repair of myelin disease: strategies and progress in animal models. Ma Med. Today (1997) 3:554–561.
  • FRANKLIN RJM, BLAKEM ORE WF: Glial-cell transplantation and plasticity in the 0-2A lineage: implications for CNS repair. Trends Neurosci. (1995) 18:151–156.
  • WINDREM MS, NUNES MC, RASHBAUM WK et al.: Fetal and adult human oligodendrocyte progenitor cell isolates myelinate the congenitally dysmyelinated brain. Nat. Med. (2004) 10:93–97.
  • BLAKEMORE WF: Remyelination of CNS axons by Schwann cells transplanted from the rat sciatic nerve. Nature (1977) 266:68–69.
  • HONMOU 0, FELTS PA, WAXMAN SG, KOCSIS J: Restoration of normal conduction properties in demyelinated spinal cord axons in the adult rat by transplantation of exogenous Schwann cells. J. Neurosci. (1996) 16:3199–3208.
  • KOHAMA I, LANKFORD KL, PREININGEROVA J, WHITE FA, VOLLMER TL, KOCSIS JD: Transplantation of cyopreserved adult
  • Expert Op/n. Investig. Drugs (2004) 13(4) human Schwann cells enhances axonal conduction in demyelinated spinal cord. Neurosci. (2001) 21:944–950.
  • SMITH PM, SIM FJ, BARNETT SC, FRANKLIN RJ: SCIP/Oct-6, Krox-20 and desert hedgehog mRNA expression during CNS remyelination by transplanted olfactory ensheathing cells. Glia (2001) 36:342–353.
  • LU J, FERON F, MACKAY-SIM A, WAITE PME: Olfactory ensheathing cells promote locomotor recovery after delayed transplantation into transected spinal cord. Brain (2002) 125:14–21.
  • BARNETT SC, ALEXANDER CL, IWASHITA Y et al.: Identification of a human olfactory ensheathing cell that can effect transplant-mediated remyelination of demyelinated CNS axons. Brain (2000) 123:1581-1588. zoo. BARNETT SC, CHANG L: Olfactory ensheathing cells and CNS repair: going solo or in need of a friend? Trends Neurosci. (2004) 27:54–60.
  • BROSTLE 0, JONES KN, LEARISH RD et al.: Embryonic stem cell-derived glial precursors: a source of myelinating transplants. Science (1999) 285:754–756.
  • •Demonstration that stem cells can differentiate into oligodendrocytes and form myelin in the CNS.
  • LIU S, QU Y, STEWART TJ et al: Embryonic stem cells differentiate into oligodendrocytes and myelinate in culture and after spinal cord transplantation. Proc. Natl. Acad. Sci. USA (2000) 97:6126–6131.
  • PLUCHINO S, QUATTRINI A, BRAMBILLA E et al.: Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature (2003) 422:688–694.
  • •First demonstration that neuronal stem cells promote recovery in an inflammatory CNS disease and that these cells can be applied systemically and are routed to the lesion.
  • MEZEY E, CHANDROSS KJ, HARTA G, MAKI RA, McKERCHER SR: Turning blood into brain: cells bearing neuronal antigens generated in vivo from bone marrow. Science (2000) 290:1779-1782. zos. NAKANO K, MIGITA M, MOCHIZUKI H, SHIMADA T: Differentiation of transplanted bone marrow cells in the adult mouse brain. Transplantation (2001) 71:1735-1740. zos. INOUE M, HONMOU 0, OKA S, HOUKIN K, HASHI K, KOCSIS J: Comparative analysis of remyelinating potential of focal and intravenous administration of autologous bone marrow cells into the demyelinated spinal cord. Glia (2003) 44:111–118.
  • BJORKLUND LM, SANCHEZ-PERNAUTE R, CHUNG S et al.: Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson model. Proc. Nati Acad. Sci. USA (2002) 99:2344–2349.
  • LEARISH RD, BROSTLE 0, ZHANG S-C, DUNCAN ID: Intraventricular transplantation of oligodendrocyte progenitors into a fetal myelin mutant results in widespread formation of myelin. Ann. Neurol (1999) 46:716-722. zos. KALKERS NF, BARKHOF F, BERGERS E, VAN SCHIJNDEL R, POLMAN CH: The effect of the neuroprotective agent riluzole on MRI papameters in patients with progressive multiple sclerosis: a pilot study. Malt. Stier. (2002) 8:532-533. Websites

Websites

  • http://www.myelin.org Website for The Myelin Project.
  • http://www.clinicaltrials.gov National Institute of Health website for information about clinical trial. Affiliation

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.